|
1
|
Riely GJ, Politi KA, Miller VA and Pao W:
Update on epidermal growth factor receptor mutations in non-small
cell lung cancer. Clin Cancer Res. 12:7232–7241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ono M and Kuwano M: Molecular mechanisms
of epidermal growth factor receptor (EGFR) activation and response
to gefitinib and other EGFR-targeting drugs. Clin Cancer Res.
12:7242–7251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou C, Wu YL, Chen G, et al: Erlotinib
versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase
3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Laurie SA and Goss GD: Role of epidermal
growth factor receptor inhibitors in epidermal growth factor
receptor wild-type non-small-cell lung cancer. J Clin Oncol.
31:1061–1069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gatzemeier U, Pluzanska A, Szczesna A, et
al: Results of a phase III trial of erlotinib (OSI-774) combined
with cisplatin and gemcitabine (GC) chemotherapy in advanced
non-small cell lung cancer (NSCLC). J Clin Oncol ASCO. 22:abs.
7010. 2004.
|
|
8
|
Han JY, Park K, Kim SW, et al:
First-SIGNAL: first-line single-agent Iressa versus gemcitabine and
cisplatin trial in never-smokers with adenocarcinoma of the lung. J
Clin Oncol. 30:1122–1128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pirker R, Pereira JR, von Pawel J, et al:
EGFR expression as a predictor of survival for first-line
chemotherapy plus cetuximab in patients with advanced
non-small-cell lung cancer: analysis of data from the phase 3 FLEX
study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar
|
|
10
|
Gridelli C, Ciardiello F, Gallo C, et al:
First-line erlotinib followed by second-line cisplatin-gemcitabine
chemotherapy in advanced non-small-cell lung cancer: the TORCH
randomized trial. J Clin Oncol. 30:3002–3011. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu JY, Shih JY, Yang CH, et al:
Second-line treatments after first-line gefitinib therapy in
advanced nonsmall cell lung cancer. Int J Cancer. 126:247–255.
2010. View Article : Google Scholar
|
|
12
|
Kumar A, Petri ET, Halmos B and Boggon TJ:
Structure and clinical relevance of the epidermal growth factor
receptor in human cancer. J Clin Oncol. 26:1742–1751. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kolch W and Pitt A: Functional proteomics
to dissect tyrosine kinase signalling pathways in cancer. Nat Rev
Cancer. 10:618–629. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sebastian S, Settleman J, Reshkin SJ,
Azzariti A, Bellizzi A and Paradiso A: The complexity of targeting
EGFR signalling in cancer: from expression to turnover. Biochim
Biophys Acta. 1766:120–139. 2006.PubMed/NCBI
|
|
15
|
Normanno N, De Luca A, Bianco C, et al:
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene.
366:2–16. 2006. View Article : Google Scholar
|
|
16
|
Irmer D, Funk JO and Blaukat A: EGFR
kinase domain mutations - functional impact and relevance for lung
cancer therapy. Oncogene. 26:5693–5701. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garassino MC, Martelli O, Broggini M, et
al: Erlotinib versus docetaxel as second-line treatment of patients
with advanced non-small-cell lung cancer and wild-type EGFR tumours
(TAILOR): a randomised controlled trial. Lancet Oncol. 14:981–988.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang J, Cheng Y, Zhao M, Zhou K, Yan H and
Zhang L: A phase II trial comparing pemetrexed with gefitinib as
the second-line treatment of nonsquamous NSCLC patients with
wild-type EGFR (CTONG0806). J Clin Oncol ASCO. 31:abs. 8042.
2013.
|
|
20
|
Rosell R, Carcereny E, Gervais R, et al:
Erlotinib versus standard chemotherapy as first-line treatment for
European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): a multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 13:239–246. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
22
|
Kobayashi K, Inoue A, Maemondo M, et al:
First-line gefitinib versus first-line chemotherapy by carboplatin
(CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC)
patients (pts) with EGFR mutations: a phase III study (002) by
North East Japan Gefitinib Study Group. J Clin Oncol ASCO. 27:abs.
8016. 2009.
|
|
23
|
Sequist LV, Bell DW, Lynch TJ and Haber
DA: Molecular predictors of response to epidermal growth factor
receptor antagonists in non-small-cell lung cancer. J Clin Oncol.
25:587–595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maheswaran S, Sequist LV, Nagrath S, et
al: Detection of mutations in EGFR in circulating lung-cancer
cells. N Engl J Med. 359:366–377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu K, Chang Q, Lu Y, et al: Gefitinib
resistance resulted from STAT3-mediated Akt activation in lung
cancer cells. Oncotarget. 4:2430–2438. 2013.PubMed/NCBI
|
|
26
|
Barré B, Vigneron A, Perkins N, Roninson
IB, Gamelin E and Coqueret O: The STAT3 oncogene as a predictive
marker of drug resistance. Trends Mol Med. 13:4–11. 2007.
View Article : Google Scholar
|
|
27
|
Dauer DJ, Ferraro B, Song L, et al: Stat3
regulates genes common to both wound healing and cancer. Oncogene.
24:3397–3408. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ai T, Wang Z, Zhang M, et al: Expression
and prognostic relevance of STAT3 and cyclin D1 in non-small cell
lung cancer. Int J Biol Markers. 27:e132–e138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamanaka Y, Nakajima K, Fukada T, Hibi M
and Hirano T: Differentiation and growth arrest signals are
generated through the cytoplasmic region of gp130 that is essential
for Stat3 activation. EMBO J. 15:1557–1565. 1996.PubMed/NCBI
|
|
30
|
Germain D and Frank DA: Targeting the
cytoplasmic and nuclear functions of signal transducers and
activators of transcription 3 for cancer therapy. Clin Cancer Res.
13:5665–5669. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dimberg A, Karlberg I, Nilsson K and Oberg
F: Ser727/Tyr701- phosphorylated Stat1 is required for the
regulation of c-Myc, cyclins, and p27Kip1 associated with
ATRA-induced G0/G1 arrest of U-937 cells. Blood. 102:254–261. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ramana CV, Chatterjee-Kishore M, Nguyen H
and Stark GR: Complex roles of Stat1 in regulating gene expression.
Oncogene. 19:2619–2627. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dimco G, Knight RA, Latchman DS and
Stephanou A: STAT1 interacts directly with cyclin D1/Cdk4 and
mediates cell cycle arrest. Cell cycle. 9:4638–4649. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamashita S, Miyagi C, Fukada T, Kagara N,
Che YS and Hirano T: Zinc transporter LIVI controls
epithelial-mesenchymal transition in zebrafish gastrula organizer.
Nature. 429:298–302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yadav A, Kumar B, Datta J, Teknos TN and
Kumar P: IL-6 promotes head and neck tumor metastasis by inducing
epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling
pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang H, Zhang G, Zhang H, et al:
Acquisition of epithelial-mesenchymal transition phenotype and
cancer stem cell-like properties in cisplatin-resistant lung cancer
cells through AKT/β-catenin/Snail signaling pathway. Eur J
Pharmacol. 723:156–166. 2014. View Article : Google Scholar
|
|
37
|
Lin L and Bivona TG: Mechanisms of
resistance to epidermal growth factor receptor inhibitors and novel
therapeutic strategies to overcome resistance in NSCLC patients.
Chemother Res Pract. 2012:8172972012.PubMed/NCBI
|
|
38
|
Chen Y-F and Fu L-W: Mechanisms of
acquired resistance to tyrosine kinase inhibitors. Acta Pharm Sin
B. 1:197–207. 2011. View Article : Google Scholar
|
|
39
|
Yeh HH, Lai WW, Chen HH, Liu HS and Su WC:
Autocrine IL-6-induced Stat3 activation contributes to the
pathogenesis of lung adenocarcinoma and malignant pleural effusion.
Oncogene. 25:4300–4309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and
Settleman J: Drug resistance via feedback activation of Stat3 in
oncogene-addicted cancer cells. Cancer Cell. 26:207–221. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim SM, Kwon OJ, Hong YK, et al:
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance
to irreversible EGFR inhibitors in non-small cell lung cancer with
T790M resistance mutation. Mol Cancer Ther. 11:2254–2264. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Song L, Rawal B, Nemeth JA and Haura EB:
JAK1 activates STAT3 activity in non-small-cell lung cancer cells
and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Mol Cancer Ther. 10:481–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Goldberg SB, Oxnard GR, Digumarthy S, et
al: Chemotherapy with Erlotinib or chemotherapy alone in advanced
non-small cell lung cancer with acquired resistance to EGFR
tyrosine kinase inhibitors. Oncologist. 18:1214–1220. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Haura EB, Sommers E, Song L, Chiappori A
and Becker A: A pilot study of preoperative gefitinib for
early-stage lung cancer to assess intratumor drug concentration and
pathways mediating primary resistance. J Thorac Oncol. 5:1806–1814.
2010. View Article : Google Scholar : PubMed/NCBI
|
